NAD+review2021

NAD+ Degrading Enzymes, Evidence for Roles During Infection.

Frontiers in molecular biosciences

confidence

Key findings

Review of NAD+ degrading enzymes (PARP, ADP-ribosyltransferases) and their roles in immune response and pathogenic infection; no clinical/biological endpoints reported.

View source on PubMed (PMID 34485381) ↗

Sample size
N/A
Population
Not applicable (review of NAD+ degrading enzymes in infection)
Dosing
N/A
Duration
N/A
Route
N/A
Blinding
not_reported
Controls
not_reported
Drug class
coenzyme
Full abstract

Declines in cellular nicotinamide adenine dinucleotide (NAD) contribute to metabolic dysfunction, increase susceptibility to disease, and occur as a result of pathogenic infection. The enzymatic cleavage of NAD+ transfers ADP-ribose (ADPr) to substrate proteins generating mono-ADP-ribose (MAR), poly-ADP-ribose (PAR) or O-acetyl-ADP-ribose (OAADPr). These important post-translational modifications have roles in both immune response activation and the advancement of infection. In particular, emergent data show viral infection stimulates activation of poly (ADP-ribose) polymerase (PARP) mediated NAD+ depletion and stimulates hydrolysis of existing ADP-ribosylation modifications. These studies are important for us to better understand the value of NAD+ maintenance upon the biology of infection. This review focuses specifically upon the NAD+ utilising enzymes, discusses existing knowledge surrounding their roles in infection, their NAD+ depletion capability and their influence within pathogenic infection.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.